HRP20191383T1 - Liječenje subpopulacija oboljelih od alzeimerove bolesti pomoću prikupljenog imunoglobulina g - Google Patents

Liječenje subpopulacija oboljelih od alzeimerove bolesti pomoću prikupljenog imunoglobulina g Download PDF

Info

Publication number
HRP20191383T1
HRP20191383T1 HRP20191383TT HRP20191383T HRP20191383T1 HR P20191383 T1 HRP20191383 T1 HR P20191383T1 HR P20191383T T HRP20191383T T HR P20191383TT HR P20191383 T HRP20191383 T HR P20191383T HR P20191383 T1 HRP20191383 T1 HR P20191383T1
Authority
HR
Croatia
Prior art keywords
preparation
use according
subject
amount
human igg
Prior art date
Application number
HRP20191383TT
Other languages
English (en)
Croatian (hr)
Inventor
David M. GELMONT
Julia Singer
Sandor Fritsch
Hans-Peter Schwarz
Original Assignee
Baxalta Incorporated
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Incorporated, Baxalta GmbH filed Critical Baxalta Incorporated
Publication of HRP20191383T1 publication Critical patent/HRP20191383T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20191383TT 2013-05-06 2014-05-05 Liječenje subpopulacija oboljelih od alzeimerove bolesti pomoću prikupljenog imunoglobulina g HRP20191383T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361855062P 2013-05-06 2013-05-06
US201361833447P 2013-06-10 2013-06-10
US201361844732P 2013-07-10 2013-07-10
US201361886464P 2013-10-03 2013-10-03
EP14730660.9A EP2994160B1 (en) 2013-05-06 2014-05-05 Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
PCT/US2014/036848 WO2014182631A1 (en) 2013-05-06 2014-05-05 Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g

Publications (1)

Publication Number Publication Date
HRP20191383T1 true HRP20191383T1 (hr) 2020-02-07

Family

ID=50943566

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191383TT HRP20191383T1 (hr) 2013-05-06 2014-05-05 Liječenje subpopulacija oboljelih od alzeimerove bolesti pomoću prikupljenog imunoglobulina g

Country Status (12)

Country Link
US (3) US20140328856A1 (enExample)
EP (2) EP2994160B1 (enExample)
JP (1) JP6424210B2 (enExample)
AU (4) AU2014262890B2 (enExample)
DK (1) DK2994160T3 (enExample)
ES (1) ES2740127T3 (enExample)
HR (1) HRP20191383T1 (enExample)
HU (1) HUE044737T2 (enExample)
LT (1) LT2994160T (enExample)
PL (1) PL2994160T3 (enExample)
PT (1) PT2994160T (enExample)
WO (1) WO2014182631A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4289820A3 (en) 2014-03-21 2024-03-13 Alzheon, Inc. Compounds for use in treating alzheimer's disease in apoe4+/+ patients
WO2016033382A1 (en) * 2014-08-27 2016-03-03 Capnia, Inc. Methods for immune globulin administration
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JP6789579B2 (ja) * 2015-09-10 2020-11-25 アルジオン， インコーポレイテッド 特定の患者集団において神経変性障害を処置する方法
CN114019170A (zh) * 2016-01-20 2022-02-08 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
HRP20211628T1 (hr) * 2016-08-18 2022-02-04 Alkahest, Inc. Frakcije krvne plazme kao tretman za kongitivne poremećaje povezane sa starenjem
BR112019022402A2 (pt) * 2017-04-26 2020-05-19 Alkahest Inc regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
SI3672631T1 (sl) 2017-08-22 2023-06-30 Biogen Ma Inc. Farmacevtski sestavki, ki vsebujejo protitelesa proti beta amiloidu
FI128916B (en) * 2018-02-05 2021-03-15 Vetcare Oy Health-promoting composition and method for its preparation
KR102276545B1 (ko) * 2019-09-05 2021-07-15 고려대학교 산학협력단 Ct 영상 기반 부위별 대뇌 피질 수축율 예측 방법 및 장치
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
CA3198827A1 (en) * 2020-10-30 2022-05-05 Rush University Medical Center Intranasal immunotherapy for the treatment of alzheimer's disease
EP4472679A1 (en) * 2022-02-03 2024-12-11 Eli Lilly and Company Regional tau imaging for diagnosing and treating alzheimer's disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (enExample) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
WO2003028668A2 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. Gammaglobulin treatment of immune disorders
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
WO2006091332A2 (en) 2005-02-23 2006-08-31 Alza Corporation Intranasal administration of active agents to the central nervous system
PL1981540T3 (pl) * 2006-01-30 2013-08-30 Grifols Therapeutics Inc Sposób leczenia i profilaktyki chorób związanych z odkładaniem się amyloidu z zastosowaniem IgM
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US9084743B2 (en) 2009-09-17 2015-07-21 Baxter International Inc. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
US8622993B2 (en) 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
SG184820A1 (en) * 2010-04-13 2012-11-29 Baxter Int Use of ventricular enlargement rate in intravenous immunoglobulin treatment of alzheimer's disease
WO2011142778A1 (en) * 2010-05-13 2011-11-17 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
JP6055412B2 (ja) * 2010-09-17 2016-12-27 バクスアルタ ゲーエムベーハー 弱酸性〜中性のｐＨにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化
KR20130139153A (ko) * 2011-01-18 2013-12-20 백스터 인터내셔널 인코포레이티드 인간 혈액 중 항-베타 아밀로이드 항체의 측정
US20120251524A1 (en) * 2011-04-01 2012-10-04 Baxter Healthcare S.A. Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease
ES2714999T3 (es) * 2011-09-24 2019-05-31 Csl Behring Gmbh Terapia de combinación que usa inmunoglobulina e inhibidor de C1

Also Published As

Publication number Publication date
AU2014262890A1 (en) 2015-11-26
PL2994160T3 (pl) 2019-10-31
JP6424210B2 (ja) 2018-11-14
AU2019202459A1 (en) 2019-05-02
AU2024201051A1 (en) 2024-03-14
ES2740127T3 (es) 2020-02-05
LT2994160T (lt) 2019-08-26
DK2994160T3 (da) 2019-08-12
US20140328856A1 (en) 2014-11-06
US20210238267A1 (en) 2021-08-05
EP2994160B1 (en) 2019-07-03
AU2020257034A1 (en) 2020-11-12
WO2014182631A1 (en) 2014-11-13
EP3552624A1 (en) 2019-10-16
EP2994160A1 (en) 2016-03-16
AU2014262890B2 (en) 2019-01-31
JP2016518411A (ja) 2016-06-23
US20190144530A1 (en) 2019-05-16
HUE044737T2 (hu) 2019-11-28
AU2019202459B2 (en) 2020-07-23
PT2994160T (pt) 2019-08-07

Similar Documents

Publication Publication Date Title
HRP20191383T1 (hr) Liječenje subpopulacija oboljelih od alzeimerove bolesti pomoću prikupljenog imunoglobulina g
HRP20150790T1 (hr) Režimi imunoterapije koji ovise o statusu apoe
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
HRP20201656T1 (hr) Neutralizacija inhibitornih putova u limfocitima
JP2013533858A5 (enExample)
JP2015532292A5 (enExample)
JP2017530130A5 (enExample)
HRP20151350T1 (hr) Neuroprotekcija kod demijelinizacijskih bolesti
JP2015505564A5 (enExample)
JP2016518411A5 (enExample)
Stieglbauer et al. Beneficial effect of rituximab monotherapy in multifocal motor neuropathy
WO2014058979A8 (en) Laquinimod for reducing thalamic damage in multiple sclerosis
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
EP3309555A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
MX2013002418A (es) Administracion de lorcaserina a individuos con daño renal.
WO2007078443A3 (en) Methods of treating unwanted immune response with random copolymers
WO2015009731A3 (en) Azacyclic constrained analogs of fty720
JP2016531853A5 (enExample)
WO2016003158A3 (ko) DX2 단백질과 p14/ARF 단백질 간의 결합을 억제하는 신규 화합물 및 상기 화합물을 유효성분으로 함유하는 암질환 치료 또는 예방용 약학조성물
SI3137093T1 (en) Treatment and prevention of Alzheimer's disease
Takatori Carboplatin/irinotecan/paclitaxel
PH12015502560B1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
Prignano Adalimumab/etanercept/infliximab Monoclonal gammopathy: 8 case reports
Provenzano Neutropenia: case report
Cathomas Denosumab/sorafenib